vaccines

News

FDA delays decision on Moderna’s RSV vaccine

Moderna’s first attempt to expand its commercial activities beyond COVID-19 vaccines, its respiratory syncytial virus (RSV) shot, has suffered a delay in the US.

News

Sanofi forges $1.2bn alliance with vaccines firm Novavax

Sanofi has licensed joint commercial rights to Novavax’s COVID-19 vaccine and will work with the biotech on the development of combined flu/COVID shots in a deal worth up

News

Novavax's chief executive John Jacobs (l) and Shah Capital's founder Himanshu Shah (r)

Activist investor urges changes to Novavax board

Shah Capital has stepped up its campaign for change at vaccine producer Novavax, lobbying against the re-election of three directors and executive pay packages in a letter

News

GSK trails after Pfizer in 5-in-1 meningococcal vaccine race

The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from P

News

Activist hedge fund seeks big shake-up at Novavax

Shah Capital has fired a broadside at the management team of Novavax, seeking a change in leadership at the vaccine company and the appointment of two handpicked directors

News

Blackstone bankrolls Moderna’s flu shot with $750m

Moderna’s efforts to develop a range of mRNA vaccines for influenza have been bolstered with funding of up to $750 million from investment firm Blackstone Life Sciences.

FDA delays decision on Moderna’s RSV vaccine

Sanofi forges $1.2bn alliance with vaccines firm Novavax

Activist investor urges changes to Novavax board

GSK trails after Pfizer in 5-in-1 meningococcal vaccine race

Activist hedge fund seeks big shake-up at Novavax

Blackstone bankrolls Moderna’s flu shot with $750m

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

vaccines

Editor's Picks